A blood test called DCP can help doctors identify vitamin K deficiency in cystic fibrosis patients, according to Gram Research analysis. In a study of 94 CF patients, about 12% had high DCP levels suggesting vitamin K problems, particularly those with advanced liver disease or poor medication adherence. This test could become a useful tool for CF care teams to monitor vitamin K status and catch deficiencies early.
People with cystic fibrosis often struggle to absorb fat-soluble vitamins like vitamin K because their pancreas doesn’t work properly. Doctors have had trouble figuring out who has vitamin K deficiency. A new study looked at whether a blood test called DCP (des-gamma-carboxy-prothrombin) could help identify vitamin K problems in CF patients. Researchers reviewed records from 94 CF patients and found that about 12% had low vitamin K levels based on the DCP test. The test seemed especially useful for spotting vitamin K issues in patients with advanced liver disease or those not taking their supplements regularly.
Key Statistics
A 2026 single-center retrospective review of 94 cystic fibrosis patients found that 11.7% had elevated DCP levels indicating vitamin K deficiency, with higher rates among those with advanced liver disease.
Among 11 CF patients with high DCP levels in a 2026 study, 27% had advanced cystic fibrosis liver disease compared to much lower rates in the normal DCP group, suggesting DCP testing could identify high-risk patients.
A 2026 analysis of 94 CF patients showed that those with high DCP levels were significantly more likely to have poor adherence to pancreatic enzyme supplements and vitamin supplementation.
The median DCP value in a 2026 study of 94 cystic fibrosis patients was 0.35 ng/mL, with a wide range of 0.1 to 11 ng/mL, demonstrating substantial variation in vitamin K status across the CF population.
The Quick Take
- What they studied: Whether a blood test called DCP can accurately measure vitamin K levels in people with cystic fibrosis
- Who participated: 94 people with cystic fibrosis (39 children and 55 adults) treated at one medical center between 2022 and 2024
- Key finding: About 12% of CF patients had high DCP levels suggesting vitamin K deficiency, and this was especially common in those with advanced liver disease or poor medication adherence
- What it means for you: If you have cystic fibrosis, this blood test could help your doctor catch vitamin K problems earlier. However, more research is needed before this becomes standard practice at all hospitals
The Research Details
Researchers looked back at medical records from 94 cystic fibrosis patients seen at one hospital between 2022 and 2024. They measured a protein in the blood called DCP, which increases when the body doesn’t have enough vitamin K. They compared patients with normal DCP levels to those with high levels to see what differences existed between the groups.
The study divided patients into two groups: those with low DCP (normal vitamin K) and those with high DCP (possible vitamin K deficiency). The researchers then looked at other health factors like age, gender, liver disease, and whether patients were taking their vitamins and pancreatic enzyme supplements regularly.
This approach is called a retrospective review because the researchers examined records from the past rather than following patients forward in time. It’s a practical way to test whether a new blood test might be useful before investing in larger, more expensive studies.
Cystic fibrosis damages the pancreas, making it hard for the body to absorb vitamins that need fat to be absorbed, including vitamin K. Vitamin K is crucial for blood clotting and bone health. Currently, doctors don’t have a reliable, easy test to check vitamin K status in CF patients. The DCP blood test could fill this gap by giving doctors a simple way to identify who needs more vitamin K supplementation.
This study has both strengths and limitations. The strength is that it looked at real patient data from actual medical practice. The limitations include: it only examined records from one hospital, so results may not apply everywhere; it’s a small study with only 94 patients; it looked backward at past records rather than following patients forward; and the researchers couldn’t control for all factors that might affect vitamin K levels. The authors themselves noted that larger, multicenter studies are needed to confirm these findings.
What the Results Show
The median DCP value in the study was 0.35 ng/mL, meaning half the patients had levels below this and half above. The range was very wide, from 0.1 to 11 ng/mL, showing that vitamin K status varied greatly among CF patients.
When researchers classified patients into groups, they found that 11 out of 94 patients (11.7%) had high DCP levels suggesting vitamin K deficiency. This 11.7% rate represents the prevalence of suboptimal vitamin K status in this CF population.
Patients with high DCP levels were significantly more likely to have advanced cystic fibrosis liver disease. Three out of the 11 patients with high DCP (27%) had this serious liver complication, compared to a much lower rate in the normal DCP group. Additionally, patients with high DCP were more likely to have other fat-soluble vitamin deficiencies and appeared to have poor adherence to taking their pancreatic enzyme supplements or vitamin pills.
The study found no significant differences in age or gender between patients with normal and high DCP levels, suggesting that vitamin K deficiency in CF isn’t simply a matter of age. The connection between high DCP levels and advanced liver disease is particularly important because it suggests the DCP test might help identify CF patients at highest risk for serious complications. The link between high DCP and poor medication adherence suggests that the test could help doctors identify patients who need better support in taking their medications.
Previous research has shown that vitamin K deficiency is common in cystic fibrosis patients, but doctors have struggled to measure it accurately. Standard blood tests for vitamin K aren’t reliable in CF patients because their fat absorption is abnormal. The DCP test, which measures an inactive form of a clotting protein that appears when vitamin K is low, offers a potentially better approach. This study is among the first to specifically evaluate DCP for this purpose in CF patients, filling an important gap in the medical literature.
This study has several important limitations. First, it only included patients from one hospital, so the results may not apply to CF patients everywhere. Second, the sample size of 94 patients is relatively small for drawing firm conclusions. Third, the study looked backward at past medical records rather than following patients forward over time, which limits what researchers can conclude about cause and effect. Fourth, the researchers couldn’t control for all factors that might affect vitamin K levels, such as diet or other medications. Finally, the study didn’t include a comparison group of healthy people without CF, so we don’t know if the DCP levels found are truly abnormal or just normal variation.
The Bottom Line
If you have cystic fibrosis, talk to your CF care team about whether DCP testing might be useful for monitoring your vitamin K status. Make sure you’re taking your pancreatic enzyme supplements and fat-soluble vitamin supplements as prescribed, since poor adherence was linked to vitamin K problems. The evidence for using DCP is promising but not yet strong enough to recommend it as standard practice everywhere. More research is needed before this becomes routine care.
This research is most relevant to people with cystic fibrosis and their doctors. It’s especially important for CF patients with advanced liver disease or those who struggle to take their medications regularly. It may also interest CF care teams and researchers working to improve vitamin monitoring in CF. People without CF don’t need to worry about this test.
If DCP testing becomes available at your CF center, you might see results within days of a blood draw. However, improvements in vitamin K status from better supplementation or medication adherence typically take weeks to months to become apparent. Long-term benefits like better bone health and reduced bleeding risk develop over years.
Frequently Asked Questions
What is DCP and why does it matter for cystic fibrosis patients?
DCP (des-gamma-carboxy-prothrombin) is a protein in the blood that increases when vitamin K levels are low. For CF patients, it offers a potentially better way to measure vitamin K status than standard tests, since CF affects how the body absorbs fat-soluble vitamins like vitamin K.
How common is vitamin K deficiency in people with cystic fibrosis?
According to a 2026 study of 94 CF patients, about 12% had vitamin K deficiency based on DCP testing. However, this may underestimate the true rate, since many CF patients may have mild deficiency that doesn’t show up on current tests.
Can I get a DCP test at my CF center right now?
DCP testing is not yet standard practice at all CF centers. Ask your CF care team whether they offer this test or can refer you to a center that does. The research is promising but still being evaluated before becoming routine care.
What should I do if I have cystic fibrosis to prevent vitamin K deficiency?
Take your pancreatic enzyme supplements with every meal containing fat, and take your fat-soluble vitamin supplements (including vitamin K) as prescribed by your CF team. Good adherence to these medications is the best way to prevent vitamin K and other fat-soluble vitamin deficiencies.
Is vitamin K deficiency dangerous in cystic fibrosis?
Yes, vitamin K deficiency can cause problems with blood clotting and bone health. The 2026 study found that CF patients with vitamin K deficiency were more likely to have advanced liver disease, suggesting it’s an important marker of overall CF severity.
Want to Apply This Research?
- Track your pancreatic enzyme supplement and vitamin K supplement adherence daily using a checklist or reminder system. Note any missed doses and correlate with any symptoms like unusual bruising or bleeding.
- Set daily phone reminders for taking pancreatic enzymes with meals and fat-soluble vitamins. Use a pill organizer to make it easier to see if you’ve taken your supplements. If you struggle with adherence, discuss barriers with your CF care team.
- If your CF center offers DCP testing, request it annually or as recommended by your doctor. Track the results over time to see if your vitamin K status is improving with better supplement adherence. Also monitor for signs of vitamin K deficiency like unusual bruising, nosebleeds, or heavy periods.
This article summarizes research findings and should not be used as medical advice. If you have cystic fibrosis or suspect vitamin K deficiency, consult your doctor or CF care team before making any changes to your treatment plan. DCP testing is not yet standard practice and availability varies by location. The findings from this single-center study need confirmation through larger, multicenter research before widespread clinical adoption.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.